The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sadulaeva I.A.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Vasiuk Yu.A.

Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Trofimenko O.S.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Yushchuk E.N.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Ivanova S.V.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Shupenina E.Yu.

Department of clinical functional diagnostics Faculty of Medicine, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov Russian Ministry of Health, Moscow, Russia

Nesterova E.A.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Obesity in metabolic syndrome, as well as kidney dysfunction

Authors:

Sadulaeva I.A., Vasiuk Yu.A., Trofimenko O.S., Yushchuk E.N., Ivanova S.V., Shupenina E.Yu., Nesterova E.A.

More about the authors

Journal: Therapeutic Archive. 2016;88(10): 93‑98

DOI: 10.17116/terarkh201688693-98

Read: 2974 times

Download PDF (RU)
Contact the author
Table of contents

OBESITY IN METABOLIC SYNDROME, AS WELL AS KIDNEY DYSFUNCTION
OBESITY IN METABOLIC SYNDROME, AS WELL AS KIDNEY DYSFUNCTION

To cite this article:

Sadulaeva IA, Vasiuk YuA, Trofimenko OS, Yushchuk EN, Ivanova SV, Shupenina EYu, Nesterova EA. Obesity in metabolic syndrome, as well as kidney dysfunction. Therapeutic Archive. 2016;88(10):93‑98. (In Russ.)
https://doi.org/10.17116/terarkh201688693-98

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Analysis of the infrastructure for physical acti­vity of the popu­lation and its asso­ciation with obesity. Russian Journal of Preventive Medi­cine. 2025;(3):46-52
A personalized approach to the diagnosis of epilepsy in obese children. Labo­ratory Service. 2025;(1):5-12
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Dietary restrictions as a risk factor for binge eating diso­rder. Russian Journal of Preventive Medi­cine. 2025;(4):123-129
Obesity in the context of the «old friends» hypo­thesis. Russian Journal of Preventive Medi­cine. 2025;(4):136-141
Premature birth and obesity: epidemiology, pathogenesis and obstetric tactics. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):29-34
Treatment and prevention of suture failure and bleeding after various bariatric inte­rventions. Piro­gov Russian Journal of Surgery. 2025;(5):79-85
Prevalence of meta­bolic syndrome among the indi­genous popu­lation in central Yaku­tia rural areas. Russian Journal of Preventive Medi­cine. 2025;(5):21-26
Effi­ciency of anthropometric surrogate indi­ces for the meta­bolic syndrome and its components diagnosing in middle-aged Moscow men. Russian Journal of Preventive Medi­cine. 2025;(5):41-48
Drinking mine­ral water for progressive resi­stance to insu­lin. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):24-30
Abstract:

The presence of metabolic syndrome (MS) in a patient allows him to be assigned to a group at high risk for atherosclerosis, cardiovascular events, coronary heart disease, and type 2 diabetes mellitus. In addition, MS negatively affects not only the heart and vessels, but also kidney function, which leads to chronic kidney disease (CKD). MS is pathogenetically associated with CKD and is an independent prognostic factor of the development of the latter, namely, the involvement of the kidney frequently determines prognosis and quality of life in these patients. The paper gives a modern view on the concept of MS and CKD and considers its main diagnostic criteria, etiology, and pathogenesis. The study of the relationships between MS and CKD may suggest that the high prevalence of kidney dysfunction in the general population is largely determined by metabolic nephropathies, including obesity-related nephropathy. The identification of risk factors and poor prognostic markers in this category of patients seems to be extremely important for the early diagnosis of the disease and their timely elimination is one of the main approaches to the comprehensive prevention of CKD in these patients.

Keywords:

hypertension
obesity
kidney dysfunction
metabolic syndrome
endothelial dysfunction
hyperinsulinemia
microalbuminuria

Authors:

Sadulaeva I.A.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Vasiuk Yu.A.

Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Trofimenko O.S.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Yushchuk E.N.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Ivanova S.V.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Shupenina E.Yu.

Department of clinical functional diagnostics Faculty of Medicine, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov Russian Ministry of Health, Moscow, Russia

Nesterova E.A.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

  1. Makolkin V. Metabolic syndrome. Meditsinskoe informatsionnoe agentstvo. Moscow; 2010. (In Russ.)
  2. Butrova S. Modern opportunities and prospects treatment of metabolic syndrome. Trudnyi patsient. 2007;5(6-7):31-34. (In Russ.)
  3. Mamedov M. According to the materials of the I International Congress on prediabetes and metabolic syndrome: acarbose recognized as the drug of choice for prevention of diabetes and myocardial infarction. Arterial'naya gipertenziya. 2005;14(3):173-177. (In Russ.)
  4. National clinical guidelines Russian Scientific Society of Cardiology. Sbornik. Pod red. Oganova R. 4-e izdanie. M.: Silitseya-Poligraf; 2011. (In Russ.)
  5. Andersen KK, Olsen TS. The obesity paradox in stroke: Lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke. 2015;10(1):99-104.  doi:10.1111/ijs.12016
  6. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano FQ, Grassi G, Zanchetti A, Sega R. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40-44.  doi:10.1161/01.HYP.0000251933.22091.24
  7. Ceska R. New US recommendations for the prevention of cardio-vascular disease (expert opinion). International Journal of heart and vascular diseases. Izdanie Fonda sodeistviya razvitiyu kardiologii. Kardioprogress. 2014;2:12-16. (In Russ.) Available at: http://www.cardioprogress.ru/downloads/c13m0i165/RUS2
  8. Mulè G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, Mongiovì R, Mezzatesta G, Andronico G, Cerasola G. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med. 2005;257(6):503-513.  doi:10.1111/j.1365-2796.2005.01493.x
  9. Schillaci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G, Franklin SS, Mannarino E. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension. 2005;5(6):1078-1082. doi:10.1161/01.HYP.0000165313.84007.7d
  10. Dinh W, Lankisch M, Nickl W, Gies M, Scheyer D, Kramer F, Scheffold T, Krahns T, Sause A, Füth R. Metabolic syndrome with or without diabetes contributes to left ventricular diastolic dysfunction. Acta Cardiol. 2011;66(2):167-174.  doi:10.2143/AC.66.2.2071247
  11. Kawamoto R, Tomita H, Oka Y, Kodama A, Kamitani A. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Int Med. 2005;44(12):1232-1238. doi:10.2169/internalmedicine.44.1232
  12. Chazova I, Mischka V. Metabolic syndrome. M.: Media Medika; 2008. (In Russ.)
  13. Millán-Núñez J, Mantilla-Morató T, Toro R, Millán-Pérez JJ, Mangas-Rojas A, Members Of The Scientific Committee Of The Hypertriglyceridemia Registry Of The Spanish Society Of Arteriosclerosis Sea. Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc. Curr Pharm Des. 2015;22(3):365-371.  doi:10.2174/1381612822666151112150831
  14. Silaghi AC, Poanta L, Valea A, Pais R, Silaghi H. Is epicardial adipose tissue assessed by echocardiography, a reliable method for visceral adipose tissue prediction? MED Utrason. 2011;13(1):15-20. http://www.medultrason.ro/assets/Magazines/Medultrason-2011-vol13-no1/04silaghi.pdf
  15. Drapkina O, Korneeva O, Chernova E. Epicardial fat and non-alcoholic fatty liver disease. Serdtse. 2012;11(4):235-243. (In Russ.)
  16. Psychari SN, Rekleiti N, Papaioannou N, Varhalama E, Drakoulis C, Apostolou TS, Iliodromitis EK. Epicardial Fat in Nonalcoholic Fatty Liver Disease: Properties and Relationships With Metabolic Factors, Cardiac Structure, and Cardiac Function. Angiology. 2016;67(1):41-48.  doi:10.1177/0003319715576672
  17. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131-145.  doi:10.1016/j.metabol.2014.10.016
  18. Smitka K, Marešová D. Adipose tissue as an endocrine organ: An Update on Pro-inflamattori and Anti- inflamattori Microenvironment. Prague Med Rep. 2015;16(2):87-111.  doi:10.14712/23362936.2015.49
  19. Yubitskaya N, Antonyuk M, Veremchuk L, Hodosova K. The role of tumor necrosis factor in the development of metabolic syndrome. Terapevticheskii arkhiv. 2009;11:59-63. (In Russ.)
  20. Thomas S, Suresh S, Sudheesh M, Vijayakumar T. Association of insulin resistance with adipocytokine levels in patients with metabolic syndrome. Indian J Clin Biochem. 2015;30(2):155-160.  doi:10.1007/s12291-014-0423-7
  21. Cardiovascular risk and chronic kidney disease: cardiovascular renal protection strategy. Clinical guidelines. Rossiiskii kardiologicheskii zhurnal. 2014;8(112):7-37. (In Russ.)
  22. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Int Med. 2004;140 (3):167-174.  doi:10.7326/0003-4819-140-3-200402030-00007
  23. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa. Japan. Kidney Int. 2006;69:369-374.
  24. Ting SM, Nair H, Ching I, Taheri S, Dasgupta I. Overweight, obesity and chronic kidney disease. Nephron Clin Pract. 2009;112(3):121-127;discussion c127. doi:10.1159/000214206
  25. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444(7121):881-887.  doi:10.1038/nature05488
  26. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3(Suppl.):1-150.  doi:10.1038/ki.2013.243
  27. Nebieridze D, Oganov R. Hyperactivity of the sympathetic nervous system: clinical significance and perspectives of correction. Kardiovaskulyarnaya terapiya i profilaktika. 2004;3:94-99. (In Russ.)
  28. Moiseev S, Fomin V. The sympathetic nervous system and the metabolic syndrome. Klinicheskaya farmakologiya i terapiya. 2004;4:70-74. (In Russ.)
  29. Gornostaeva E, Novikov M, Beloborodov A, Akarachkova E, Shilov E, Shvarkov S. Vegetative imbalance in patients with the metabolic syndrome: the role of hyperfiltration - an early marker of renal disease. Terapevticheskii arkhiv. 2010;6:49-53. (In Russ.)
  30. Kalashnikova M. Metabolic syndrome: a modern view on the concept, methods of prevention and treatment. Effektivnaya farmakoterapiya. 2013;6(55):52-63. (In Russ.) Available at: http://umedp.ru/
  31. Krasnov E, Moiseev S, Fomin V. Neurological aspects of the problem of obesity. Klinicheskaya meditsina. 2005;4:9-14. (In Russ.)
  32. Arutyunov G, Oganezova L. Hyperfiltration and metabolic syndrome. Sistemnye gipertenzii. 2009;1:66-70. (In Russ.)
  33. Kobalava Z, Moiseev V. Concept of cardiorenal and metabolic relations in modern preventive cardiology. Kardiovaskulyarnaya terapiya i profilaktika. 2008;4:4-7. (In Russ.)
  34. Korolczuk A, Dudka J. Increased risk of cardiovascular complications in chronic kidney disease: a possible role of leptin. Curr Pharm Des. 2014;20(4):666-674.  doi:10.2174/13816128113199990013
  35. Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A. Differential Role of Leptin and Adiponectin in Cardiovascular System. Int J Endocrinol. 2015;2015:534320. doi:10.1155/2015/534320
  36. Severova M, Loginova E, Gallyamov M, Kravtsov N, Rodina A, North M, Fomin V, Mukhin N. The relationship of the plasma concentrations of leptin and adiponectin with renal disease in patients with metabolic syndrome and nonalcoholic fatty liver disease. Klinicheskaya nefrologiya. 2011;1:30-34. (In Russ.)
  37. Nelson R, Antonetti I, Bisognano JD, Sloand J. Obesity-related cardiorenal syndrome. J Clin Hypertens. 2010;12(1):59-63.  doi:10.1111/j.1751-7176.2009.00205.x
  38. Severova M, Fomin V, Lebedeva M, Sorokin Yu, Saginova E, Minakova E, Gallyamov M, Mukhin N. The relationship of obstructive sleep apnea with signs of non-alcoholic fatty liver disease, and estimated glomerular filtration rate and metabolic syndrome. Terapevticheskii arkhiv. 2010;6:35-39. (In Russ.)
  39. Rajan T, Barbour SJ, White CT, Levin A. Low birth weight and nephron mass and their role in the progression of chronic kidney disease: a case report on identical twins with Alport disease. Nephrol Dial Transplant. 2011;26(12):4136-4139. doi:10.1093/ndt/gfr252
  40. Krasnov E, Fedorov E, Kutyrina I, Fomin V. Renal disease in obesity: clinical, pathogenic and therapeutic aspects. Vrach. 2005;6:5-7. (In Russ.)
  41. Shilov E, Levankovskaya E, Novikova M. New approaches to the treatment of patients with chronic kidney disease and metabolic syndrome. Klinicheskaya nefrologiya. 2012;2:72-76. (In Russ.)
  42. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16:1325-1333.
  43. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W, De Santo NG. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The GUBBIO Population Study. Arch Intern Med. 1998;158(17):1933-1939. doi:10.1001/archinte.158.17.1933
  44. Bonnet F , Marre M, Halimi JM, Stengel B, Lange C, Laville M, Tichet J, Balkau B. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens. 2006;24(6):1157-1163.
  45. Kim H, Kim HJ, Shin N, Han M, Park H, Kim M, Kwon H, Choi SY, Heo NJ. Visceral obesity is associated with microalbuminuria in nondiabetic Asians. Hypertens Res. 2014;37(7):679-684.  doi:10.1038/hr.2014.47
  46. Arutyunov G, Oganezova L. Subclinical inflammation in hypertension: the impact on the tubular-interstitial tissue and renal function. Serdtse. 2010;6(56):345-349. (In Russ.)
  47. Kobalava Zh, Kotovskaya Y. Hypertension in the XXI century: achievements, problems, prospects. (2nd edition, supplemented and revised). Moscow: Bionika Media; 2015. (In Russ.)
  48. Arutyunov G, Oganezova L Hyperfiltration problem in clinical practice. Klinicheskaya nefrologiya. 2009;1:29-40. (In Russ.)
  49. Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, Sattar N, Zukowska-Szczechowska E, Dominiczak AF. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int. 2007;71(8):816-821.
  50. Novikova M, Shilov E, Borisov V. Hyperfiltration - an early sign of chronic kidney disease development in men with metabolic syndrome. Terapevticheskii arkhiv. 2010;82: 2-55. (In Russ.)
  51. Ogna A, Forni Ogna V, Bochud M, Guessous I, Paccaud F, Burnier M, Wuerzner G. Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. Eur J Nutr. 2015 May 14. [Epub ahead of print].
  52. Chandra A, Biersmith M, Tolouian R. Obesity and kidney protection. J Nephropathol. 2014;3(3):91-97.  doi:10.12860/jnp.2014.18
  53. Ezequiel DG, Costa MB, Chaoubah A, de Paula RB. Weight loss improves renal hemodynamics in patients with metabolic syndrome. J Bras Nefrol. 2012;34(1):36-42.  doi:10.1590/S0101-28002012000100006
  54. Xia F, Liu G, Shi Y, Zhang Y. Impact of microalbuminuria on incident coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis of prospective studies. Int J Clin Exp Med. 2015;8(1):1-9.
  55. Bendriss L, Lebbaq A, Jallal H, Mrani S, Khatouri A. Usefulness of microalbuminuria in the metabolic syndrome as a predictor of cardiovascular disease. Prospective study about 78 cases. Ann Cardiol Angeiol (Paris). 2012;61(1):15-19.  doi:10.1016/j.ancard.2011.04.011
  56. Praga M, Morales E, Herrero JC, Pérez Campos A, Domínguez-Gil B, Alegre R, Vara J, Martínez MA. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis. 1999;33(1):52-58.
  57. Praga M, Hernández E, Morales E, Campos AP, Valero MA, Martínez MA, León M. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16(9):1790-1798. doi:10.1093/ndt/16.9.1790
  58. Liou TL, Lin MW, Hsiao LC, Tsai TT, Chan WL, Ho LT, Hwu CM. Is hyperuricemia another facet of the metabolic syndrome? J Chin Med Assoc. 2006;69(3):104-109.  doi:10.1016/S1726-4901(09)70186-8
  59. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269-275.  doi:10.1097/HJH.0b013e3282f240bf
  60. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553-3562. doi:10.1681/ASN.2005050572
  61. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234-1242.
  62. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237-247.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.